Catalog Home Page

Publications: Fletcher, Susan

Stats for Fletcher, Susan
Export as [feed] RSS
Group by: Publication Type | Year
Number of items: 215.

Journal Article

Servián-Morilla, E., Cabrera-Serrano, M., Rivas-Infante, E., Carvajal, A., Lamont, P.J., Pelayo-Negro, A.L., Ravenscroft, G., Junckerstorff, R., Dyke, J.M., Fletcher, S., Adams, A.M., Mavillard, F., Fernández-García, M.A., Nieto-González, J.L., Laing, N.G. and Paradas, C. (2019) Altered myogenesis and premature senescence underlie human TRIM32-related myopathy. Acta Neuropathologica Communications, 7 (1).

Callus, B.A., Finch-Edmondson, M.L., Fletcher, S. and Wilton, S.D. (2019) YAPping about and not forgetting TAZ. FEBS Letters, 593 (3). pp. 253-276.

West, K.A., Fletcher, S. and Wilton, S.D. (2018) Antisense oligonnucleotide treatment of COL7A1 causes non-specific splice modifications. Journal of Gene Medicine, 20 (1).

Flynn, L.L., Mitrpant, C., Pitout, I.L., Fletcher, S. and Wilton, S.D. (2018) Antisense oligonucleotide mediated terminal intron retention of the SMN2 transcript. Molecular Therapy - Nucleic Acids, 11 . pp. 91-102.

Le, B.T., Raguraman, P., Kosbar, T.R., Fletcher, S., Wilton, S.D. and Veedu, R.N. (2018) Antisense oligonucleotides targeting angiogenic factors as potential cancer therapeutics. Molecular Therapy - Nucleic Acids, 14 (1). pp. 142-157.

Bellgard, M.I., Napier, K.R., Bittles, A.H., Szer, J., Fletcher, S., Zeps, N., Hunter, A.A. and Goldblatt, J. (2018) Design of a framework for the deployment of collaborative independent rare disease-centric registries: Gaucher disease registry model. Blood Cells, Molecules, and Diseases, 68 . pp. 232-238.

Bao, L.T., Herdewijn, P., Filichev, V.V., Wilton, S.D., Fletcher, S. and Veedu, R.N. (2018) Exploring novel therapeutic chemistries in exon-skipping for duchenne muscular dystrophy. Journal of Gene Medicine, 20 (1).

McLenachan, S., Zhang, D., Zhang, X., Chen, S-C, Lamey, T., Thompson, J.A., McLaren, T., De Roach, J.N., Fletcher, S. and Chen, F.K. (2018) Generation of two induced pluripotent stem cell lines from a patient with dominant PRPF31 mutation and a related non-penetrant carrier. Stem Cell Research, 34 .

Aung-Htut, M.T., West, K., Barrett, L., Cardwell, K., Schnell, F.J., Fletcher, S. and Wilton, S.D. (2018) Late onset Pompe disease: Rescue of acid alpha-glucosidase expression by splice modification. Journal of Gene Medicine, 20 (1).

Greer, K., Fletcher, S. and Wilton, S.D. (2018) Multiple exon skipping to correct duplications in the dystrophin gene. Journal of Gene Medicine, 20 (1).

Li, D., Mastaglia, F.L., Fletcher, S. and Wilton, S.D. (2018) Precision medicine through antisense oligonucleotide-mediated exon skipping. Trends in Pharmacological Sciences, 39 (11). pp. 982-994.

Martinovich, K.M., Wilton, S.D., Fletcher, S., Kicic, A. and Stick, S.M. (2018) Rescue of CFTR function impaired by mutations in EXON 15 in children with cyctic fibrosis. Pediatric Pulmonology, 53 (S2). S224-S224.

Martinovich, K.M., Kicic, A., Fletcher, S., Wilton, S.D. and Stick, S.M. (2018) Rescuing CFTR function caused by mutation specific polymorphisms in cystic fibrosis patients. The Journal of Gene Medicine, 20 (1).

Li, D.H., Greer, K., West, K., Addams, A., Fletcher, S. and Wilton, S. (2018) Small chemical modulation of induced alternative splicing. Journal of Gene Medicine, 20 (1).

Viola, H.M., Johnstone, V.P.A., Adams, A.M., Fletcher, S. and Hool, L.C. (2018) A morpholino oligomer therapy regime that restores mitochondrial function and prevents mdx cardiomyopathy. JACC: Basic to Translational Science, 3 (3). pp. 391-402.

Hoffmann, K., Milech, N., Juraja, S.M., Cunningham, P.T., Stone, S.R., Francis, R.W., Anastasas, M., Hall, C.M., Heinrich, T., Bogdawa, H.M., Winslow, S., Scobie, M.N., Dewhurst, R.E., Florez, L., Ong, F., Kerfoot, M., Champain, D., Adams, A.M., Fletcher, S., Viola, H.M., Hool, L.C., Connor, T., Longville, B.A.C., Tan, Y-F, Kroeger, K., Morath, V., Weiss, GA., Skerra, A., Hopkins, R.M. and Watt, P.M. (2018) A platform for discovery of functional cell-penetrating peptides for efficient multi-cargo intracellular delivery. Scientific Reports, 8 (1).

Martinovich, K.M., Shaw, N.C., Kicic, A., Schultz, A., Fletcher, S., Wilton, S.D. and Stick, S.M. (2018) The potential of antisense oligonucleotide therapies for inherited childhood lung diseases. Molecular and Cellular Pediatrics, 5 (1).

McIntosh, C.S., Aung-Htut, M.T., Fletcher, S. and Wilton, S.D. (2018) The use of antisense oligonucleotide-mediated exon skipping to treat spinocerebellar ataxia type 3. Journal of Gene Medicine, 20 (1).

Bellgard, M.I., Chartres, N., Watts, G.F., Wilton, S., Fletcher, S., Hunter, A. and Snelling, T. (2017) Comprehending the health informatics spectrum: Grappling with system entropy and advancing quality clinical research. Frontiers in Public Health, 5 .

Huang, D., Fletcher, S., Wilton, S., Palmer, N., McLenachan, S., Mackey, D. and Chen, F. (2017) Inherited retinal disease therapies targeting precursor messenger ribonucleic acid. Vision, 1 (3). p. 22.

Wilton, S. and Fletcher, S. (2017) Making sense in Duchenne muscular dystrophy: Slowing the natural progression of muscle wasting. Journal of the Neurological Sciences, 381 (Supp.). p. 58.

Le, B.T., Adams, A.M., Fletcher, S., Wilton, S.D. and Veedu, R.N. (2017) Rational design of short locked Nucleic Acid-Modified 2′- O -Methyl antisense oligonucleotides for efficient exon-skipping in vitro. Molecular Therapy - Nucleic Acids, 9 . pp. 155-161.

Muntoni, F., Fletcher, S. and Wilton, S. (2017) Response to “Railroading at the FDA". Nature Biotechnology, 35 (3). pp. 207-209.

Fletcher, S., Bellgard, M.I., Price, L., Akkari, A.P. and Wilton, S.D. (2017) Translational development of splice-modifying antisense oligomers. Expert Opinion on Biological Therapy, 17 (1). pp. 15-30.

Viola, H.M., Johnstone, V.P.A., Adams, A.M., Fletcher, S. and Hool, L.C. (2017) Treatment of Adult mdx Mice with Phosphorodiamidate Morpholino Oligomer Restores Cardiac Mitochondrial Energetics and Prevents the Dystrophic Cardiomyopathy. Biophysical Journal, 112 (3). 245a.

Fraidenraich, D., Toh, Z.Y.C., Thandar Aung-Htut, M., Pinniger, G., Adams, A.M., Krishnaswarmy, S., Wong, B.L., Fletcher, S. and Wilton, S.D. (2016) Deletion of dystrophin In-Frame Exon 5 leads to a severe phenotype: Guidance for Exon skipping strategies. PloS one, 11 (1). e0145620.

Bao, T.L., Veedu, R.N., Fletcher, S. and Wilton, S.D. (2015) Antisense oligonucleotide development for the treatment of muscular dystrophies. Expert Opinion on Orphan Drugs, 4 (2). pp. 139-152.

Greer, K., Mizzi, K., Rice, E., Kuster, L., Barrero, R.A., Bellgard, M.I., Lynch, B.J., Foley, A.R., O Rathallaigh, E., Wilton, S.D. and Fletcher, S. (2015) Pseudoexon activation increases phenotype severity in a Becker muscular dystrophy patient. Molecular Genetics & Genomic Medicine, 3 (4). pp. 320-326.

Aaldering, L.J., Tayeb, H., Krishnan, S., Fletcher, S., Wilton, S.D. and Veedu, R.N. (2015) Smart functional nucleic acid chimeras: Enabling tissue specific RNA targeting therapy. RNA Biology, 12 (4). pp. 412-425.

Wilton, S.D., Veedu, R.N. and Fletcher, S. (2015) The emperor's new dystrophin: Finding sense in the noise. Trends in Molecular Medicine, 21 (7). pp. 417-426.

Bellgard, M.I., Napier, K., Render, L., Radochonski, M., Lamont, L., Graham, C., Wilton, S.D., Fletcher, S., Goldblatt, J., Hunter, A.A. and Weeramanthri, T. (2015) A registry framework enabling patient-centred care. Studies in Health Technology and Informatics, 214 . pp. 8-14.

Luo, Y-B, Mitrpant, C., Adams, A.M., Johnsen, R.D., Fletcher, S., Mastaglia, F.L. and Wilton, S.D. (2014) Antisense oligonucleotide induction of progerin in human myogenic cells. PLoS ONE, 9 (6).

Wilton, S.D., Fletcher, S. and Flanigan, K.M. (2014) Dystrophin as a therapeutic biomarker: Are we ignoring data from the past? Neuromuscular Disorders, 24 (6). pp. 463-466.

Viola, H.M., Adams, A.M., Davies, S.M.K., Fletcher, S., Filipovska, A. and Hool, L.C. (2014) Impaired functional communication between the L-type calcium channel and mitochondria contributes to metabolic inhibition in the mdx heart. Proceedings of the National Academy of Sciences of the United States of America, 111 (28). E2905-E2914.

Bellgard, M.I., Sleeman, M.W., Guerrero, F.D., Fletcher, S., Baynam, G., Goldblatt, J., Rubinstein, Y., Bell, C., Groft, S., Barrero, R., Bittles, A.H., Wilton, S.D., Mason, C.E. and Weeramanthri, T. (2014) Rare disease research roadmap: Navigating the bioinformatics and translational challenges for improved patient health outcomes. Health Policy and Technology, 3 (4). pp. 325-335.

Greer, K.L., Lochmüller, H., Flanigan, K., Fletcher, S. and Wilton, S.D. (2014) Targeted exon skipping to correct exon duplications in the dystrophin gene. Molecular Therapy — Nucleic Acids, 3 (3). e155.

Fletcher, S., Meloni, P.L., Johnsen, R.D., Wong, B.L., Muntoni, F. and Wilton, S.D. (2013) Antisense suppression of donor splice site mutations in the dystrophin gene transcript. Molecular Genetics & Genomic Medicine, 1 (3). pp. 162-173.

Krishnaswamy, S., Fletcher, S., Wong, B.L. and Wilton, S.D. (2013) Exceptions to exceptions in the Duchenne: Becker dystrophin reading frame. The Journal of Gene Medicine, 15 (8-9). p. 336.

Fletcher, S. and Wilton, S.D. (2013) Exon skipping and Duchenne muscular dystrophy: A clinical trial update. The Journal of Gene Medicine, 15 (8-9). p. 330.

Buratti, E., Mitrpant, C., Porensky, P., Zhou, H., Price, L., Muntoni, F., Fletcher, S., Wilton, S.D. and Burghes, A.H.M. (2013) Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: Towards a treatment for spinal muscular atrophy. PLoS ONE, 8 (4). e62114.

Luo, Y-B, Mitrpant, C., Johnsen, R.D., Fabian, V.A., Fletcher, S., Mastaglia, F.L. and Wilton, S.D. (2013) Investigation of age-related changes in LMNA splicing and expression of progerin in human skeletal muscles. International Journal of Clinical and Experimental Pathology, 6 (12). pp. 2778-2786.

Luo, Y-B, Mitrpant, C., Johnsen, R., Fabian, V., Needham, M., Fletcher, S., Wilton, S.D. and Mastaglia, F.L. (2013) Investigation of splicing changes and post-translational processing of LMNA in sporadic inclusion body myositis. International Journal of Clinical and Experimental Pathology, 6 (9). pp. 1723-1733.

Fletcher, S., Viola, H.M., Adams, A.M., Wilton, S.D. and Hool, L.C. (2013) P.11.5 PMO-mediated dystrophin exon 23 skipping restores mitochondrial function in the mdx mouse heart. Neuromuscular Disorders, 23 (9-10). p. 800.

Luo, Y-B, Johnsen, R.D., Griffiths, L., Needham, M., Fabian, V.A., Fletcher, S., Wilton, S.D. and Mastaglia, F.L. (2013) Primary over-expression of AβPP in muscle does not lead to the development of inclusion body myositis in a new lineage of the MCK-AβPP transgenic mouse. International Journal of Experimental Pathology, 94 (6). pp. 418-425.

Fraidenraich, D., Pigozzo, S.R., Da Re, L., Romualdi, C., Mazzara, P.G., Galletta, E., Fletcher, S., Wilton, S.D. and Vitiello, L. (2013) Revertant Fibers in the mdx Murine Model of Duchenne Muscular Dystrophy: An Age- and Muscle-Related reappraisal. PLoS ONE, 8 (8). e72147.

Adkin, C.F., Meloni, P.L., Fletcher, S., Adams, A.M., Muntoni, F., Wong, B. and Wilton, S.D. (2012) Multiple exon skipping strategies to by-pass dystrophin mutations. Neuromuscular Disorders, 22 (4). pp. 297-305.

Barrett, L.W., Fletcher, S. and Wilton, S.D. (2012) Regulation of eukaryotic gene expression by the untranslated gene regions and other non-coding elements. Cellular and Molecular Life Sciences, 69 (21). pp. 3613-3634.

Fletcher, S., Adkin, C.F., Meloni, P., Wong, B., Muntoni, F., Kole, R., Fragall, C., Greer, K., Johnsen, R. and Wilton, S.D. (2012) Targeted exon skipping to address “Leaky” mutations in the dystrophin gene. Molecular Therapy — Nucleic Acids, 1 (10). e48.

Both, G., Alexander, I., Fletcher, S., Nicolson, T.J., Rasko, J.E.J., Wilton, S.D. and Symonds, G. (2011) Gene therapy: Therapeutic applications and relevance to pathology. Pathology, 43 (6). pp. 642-656.

Fragall, C.T., Adams, A.M., Johnsen, R.D., Kole, R., Fletcher, S. and Wilton, S.D. (2011) Mismatched single stranded antisense oligonucleotides can induce efficient dystrophin splice switching. BMC Medical Genetics, 12 (1).

Laing, N.G., Davis, M.R., Bayley, K., Fletcher, S. and Wilton, S.D. (2011) Molecular diagnosis of Duchenne muscular dystrophy: Past, present and future in relation to implementing therapies. The Clinical Biochemist: Reviews, 32 (3). pp. 129-134.

Wilton, S.D. and Fletcher, S. (2011) RNA Splicing Manipulation: Strategies to Modify Gene Expression for a Variety of Therapeutic Outcomes. Current Gene Therapy, 11 (4). pp. 259-275.

Fletcher, S., Adams, A.M., Johnsen, R.D., Greer, K., Moulton, H.M. and Wilton, S.D. (2010) Dystrophin isoform induction In Vivo by Antisense-mediated alternative splicing. Molecular Therapy, 18 (6). pp. 1218-1223.

Forrest, S., Meloni, P.L., Muntoni, F., Kim, J., Fletcher, S. and Wilton, S.D. (2010) Personalized exon skipping strategies to address clustered non-deletion dystrophin mutations. Neuromuscular Disorders, 20 (12). pp. 810-816.

Goyenvalle, A., Babbs, A., Powell, D., Kole, R., Fletcher, S., Wilton, S.D. and Davies, K.E. (2010) Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient Mice by Morpholino-oligomer-mediated Exon-skipping. Molecular Therapy, 18 (1). pp. 198-205.

Wilton, S. and Fletcher, S. (2010) Splice modification to restore functional dystrophin synthesis in duchenne muscular dystrophy. Current Pharmaceutical Design, 16 (8). pp. 988-1001.

Mitrpant, C., Fletcher, S., Iversen, P.L. and Wilton, S.D. (2009) By-passing the nonsense mutation in the 4CV mouse model of muscular dystrophy by induced exon skipping. The Journal of Gene Medicine, 11 (1). pp. 46-56.

Madden, H.R., Fletcher, S., Davis, M.R. and Wilton, S.D. (2009) Characterization of a complex Duchenne muscular dystrophy-causing dystrophin gene inversion and restoration of the reading frame by induced exon skipping. Human Mutation, 30 (1). pp. 22-28.

Mitrpant, C., Fletcher, S. and Wilton, S. (2009) Personalised genetic intervention for duchenne muscular dystrophy: Antisense oligomers and exon skipping. Current Molecular Pharmacology, 2 (1). pp. 110-121.

Doran, P., Wilton, S.D., Fletcher, S. and Ohlendieck, K. (2009) Proteomic profiling of antisense-induced exon skipping reveals reversal of pathobiochemical abnormalities in dystrophic mdx diaphragm. Proteomics, 9 (3). pp. 671-685.

Mitrpant, C., Adams, A.M., Meloni, P.L., Muntoni, F., Fletcher, S. and Wilton, S.D. (2009) Rational design of antisense oligomers to induce dystrophin exon skipping. Molecular Therapy, 17 (8). pp. 1418-1426.

Wilton, S.D. and Fletcher, S. (2008) Exon skipping and Duchenne muscular dystrophy: Hope, hype and how feasible? Neurology India, 56 (3). pp. 254-262.

Laws, N., Cornford-Nairn, R.A., Irwin, N., Johnsen, R., Fletcher, S., Wilton, S.D. and Hoey, A.J. (2008) Long-term administration of antisense oligonucleotides into the paraspinal muscles of mdx mice reduces kyphosis. Journal of Applied Physiology, 105 (2). pp. 662-668.

Wilton, S. and Fletcher, S. (2008) T.I.4 Splice manipulation therapies: Opportunities and challenges. Neuromuscular Disorders, 18 (9-10). p. 831.

Wilton, S., Mitrpant, C., Meloni, P., Adams, A. and Fletcher, S. (2008) T.P.2.01 Antisense oligomer design: Targeting and assay systems. Neuromuscular Disorders, 18 (9-10). p. 756.

Fletcher, S., Davis, M., MADDEN, H. and Wilton, S. (2008) T.P.2.03 Characterisation of a complex dystrophin mutation: Assume nothing when designing exon skipping strategies. Neuromuscular Disorders, 18 (9-10). p. 757.

Fletcher, S., Steinhaus, J., Mitrpant, C., Meloni, P. and Wilton, S. (2008) T.P.2.09 Induced exon skipping in normal and mdx muscle. Neuromuscular Disorders, 18 (9-10). pp. 758-759.

Wilton, S.D., Fall, A.M., Harding, P.L., McClorey, G., Coleman, C. and Fletcher, S. (2007) Antisense Oligonucleotide-induced exon skipping across the human dystrophin gene transcript. Molecular Therapy, 15 (7). pp. 1288-1296.

Adams, A.M., Harding, P.L., Iversen, P.L., Coleman, C., Fletcher, S. and Wilton, S.D. (2007) Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: Cocktails and chemistries. BMC Molecular Biology, 8 (1).

Fletcher, S., Moulton, H.M., Neuman, B.W., McClorey, G., Stein, D.A., Abes, S., Wilton, S.D., Buchmeier, M.J., Lebleu, B. and Iversen, P.L. (2007) Cell-penetrating peptide–morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo. Biochemical Society Transactions, 35 (4). pp. 826-828.

Fletcher, S., Honeyman, K., Fall, A.M., Harding, P.L., Johnsen, R.D., Steinhaus, J.P., Moulton, H.M., Iversen, P.L. and Wilton, S.D. (2007) Morpholino Oligomer–mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. Molecular Therapy, 15 (9). pp. 1587-1592.

Harding, P.L., Fall, A.M., Honeyman, K., Fletcher, S. and Wilton, S.D. (2007) The influence of antisense oligonucleotide length on dystrophin exon skipping. Molecular Therapy, 15 (1). pp. 157-166.

Wilton, S.D. and Fletcher, S. (2006) Modification of pre-mRNA processing: Application to dystrophin expression. Current Opinion in Molecular Therapeutics, 8 (2). pp. 130-135.

McClorey, G., Moulton, H.M., Iversen, P.L., Fletcher, S. and Wilton, S.D. (2006) Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Therapy, 13 (19). pp. 1373-1381.

Fletcher, S., Honeyman, K., Fall, A.M., Harding, P.L., Johnsen, R.D. and Wilton, S.D. (2006) Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide. The Journal of Gene Medicine, 8 (2). pp. 207-216.

McClorey, G., Fall, A.M., Moulton, H.M., Iversen, P.L., Rasko, J.E., Ryan, M., Fletcher, S. and Wilton, S.D. (2006) Induced dystrophin exon skipping in human muscle explants. Neuromuscular Disorders, 16 (9-10). pp. 583-590.

Fall, A.M., Johnsen, R., Honeyman, K., Iversen, P., Fletcher, S. and Wilton, S.D. (2006) Induction of revertant fibres in the mdx mouse using antisense oligonucleotides. Genetic Vaccines and Therapy, 4 (1). p. 3.

Wilton, S.D. and Fletcher, S. (2005) Antisense oligonucleotides, exon skipping and the dystrophin gene transcript. Acta Myologica : Myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology, 24 (3). pp. 222-229.

Wilton, S.D. and Fletcher, S. (2005) Antisense oligonucleotides in the treatment of Duchenne muscular dystrophy: Where are we now? Neuromuscular Disorders, 15 (6). pp. 399-402.

Wilton, S. and Fletcher, S. (2005) RNA splicing manipulation: Strategies to modify gene expression for a variety of therapeutic outcomes. Current Gene Therapy, 5 (5). pp. 467-483.

McClorey, G., Fletcher, S. and Wilton, S. (2005) Splicing intervention for Duchenne muscular dystrophy. Current Opinion in Pharmacology, 5 (5). pp. 529-534.

Gebski, B.L., Errington, S.J., Johnsen, R.D., Fletcher, S. and Wilton, S.D. (2005) Terminal antisense oligonucleotide modifications can enhance induced exon skipping. Neuromuscular Disorders, 15 (9-10). pp. 622-629.

Wells, K.E., Fletcher, S., Mann, C.J., Wilton, S.D. and Wells, D.J. (2003) Enhanced in vivo delivery of antisense oligonucleotides to restore dystrophin expression in adult mdx mouse muscle. FEBS Letters, 552 (2-3). pp. 145-149.

Lu, Q.L., Mann, C.J., Lou, F., Bou-Gharios, G., Morris, G.E., Xue, S-A, Fletcher, S., Partridge, T.A. and Wilton, S.D. (2003) Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nature Medicine, 9 (8). pp. 1009-1014.

Gebski, B.L., Mann, C.J., Fletcher, S. and Wilton, S.D. (2003) Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. Human Molecular Genetics, 12 (15). pp. 1801-1811.

Errington, S.J., Mann, C.J., Fletcher, S. and Wilton, S.D. (2003) Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene. The Journal of Gene Medicine, 5 (6). pp. 518-527.

Mann, C.J., Honeyman, K., McClorey, G., Fletcher, S. and Wilton, S.D. (2002) Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy. The Journal of Gene Medicine, 4 (6). pp. 644-654.

Mann, C.J., Honeyman, K., Cheng, A.J., Ly, T., Lloyd, F., Fletcher, S., Morgan, J.E., Partridge, T.A. and Wilton, S.D. (2001) Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proceedings of the National Academy of Sciences of the United States of America, 98 (1). pp. 42-47.

Fletcher, S., Ly, T., Duff, R.M., Howell, J.Mc.C. and Wilton, S.D. (2001) Cryptic splicing involving the splice site mutation in the canine model of Duchenne muscular dystrophy. Neuromuscular Disorders, 11 (3). pp. 239-243.

Gilbert, R., Nalbantoglu, J., Howell, J.Mc.C., Davies, L., Fletcher, S., Amalfitano, A., Petrof, B.J., Kamen, A., Massie, B. and Karpati, G. (2001) Dystrophin expression in muscle following gene transfer with a fully deleted ("Gutted") adenovirus is markedly improved by Trans-acting adenoviral gene products. Human Gene Therapy, 12 (14). pp. 1741-1755.

Fletcher, S., Carville, K.S., Howell, J.M., Mann, C.J. and Wilton, S.D. (2001) Evaluation of a short interspersed nucleotide element in the 3' untranslated region of the defective dystrophin gene of dogs with muscular dystrophy. American Journal of Veterinary Research, 62 (12). pp. 1964-1968.

Fletcher, S., Wilton, S.D. and Howell, J.Mc.C. (2000) Gene therapy and molecular approaches to the treatment of hereditary muscular disorders. Current Opinion in Neurology, 13 (5). pp. 553-560.

Honeyman, K., Carville, K.S., Howell, J.M., Fletcher, S. and Wilton, S.D. (1999) Development of a snapback method of single-strand conformation polymorphism analysis for genotyping Golden Retrievers for the X-linked muscular dystrophy allele. American Journal of Veterinary Research, 60 (6). pp. 734-7.

Wilton, S.D., Lloyd, F., Carville, K., Fletcher, S., Honeyman, K., Agrawal, S. and Kole, R. (1999) Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscular Disorders, 9 (5). pp. 330-338.

Pari, G., Shoubridge, E., DiMauro, S., Tsujino, S., Crerar, M., Shanske, S., Lloyd, F., Collins, T., Fletcher, S., Howell, J., Nalbantoglu, J. and Karpati, G. (1998) Adenovirus-mediated myophosphorylase gene transfer in myophosphorylase-deficient cells in vitro. Muscle & Nerve, Supplement 7 . S127.

Howell, J.M., Fletcher, S., O'Hara, A., Johnsen, R.D., Lloyd, F. and Kakulas, B.A. (1998) Direct dystrophin and reporter gene transfer into dog muscle in vivo. Muscle & Nerve, 21 (2). pp. 159-165.

Howell, J., Fletcher, S., O'Hara, A., Collins, T., Kakulas, B., Karpati, G. and Lochmueller, H. (1998) Golden retriever muscular dystrophy and the development of genetherapy regimes for duchenne muscular dystrophy. Muscle & Nerve, Supplement 7 . S88.

Howell, J.M., Lochmüller, H., O'Hara, A., Fletcher, S., Kakulas, B.A., Massie, B., Nalbantoglu, J. and Karpati, G. (1998) High-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscle of dystrophic dogs: Prolongation of expression with immunosuppression. Human Gene Therapy, 9 (5). pp. 629-634.

Kay, P.H., Harmon, D., Fletcher, S., Robertson, T., Ziman, M. and Papadimitriou, J.M. (1998) Pax7 includes two polymorphic homeoboxes which contain rearrangements associated with differences in the ability to regenerate damaged skeletal muscle in adult mice. The International Journal of Biochemistry & Cell Biology, 30 (2). pp. 261-269.

Wilton, S.D., Honeyman, K., Fletcher, S. and Laing, N.G. (1998) Snapback SSCP analysis: Engineered conformation changes for the rapid typing of known mutations. Human Mutation, 11 (3). pp. 252-258.

Ziman, M.R., Fletcher, S. and Kay, P.H. (1997) Alternate Pax7 transcripts are expressed specifically in skeletal muscle, brain and other organs of adult mice. The International Journal of Biochemistry & Cell Biology, 29 (7). pp. 1029-1036.

Howell, J.Mc.C., Fletcher, S., Kakulas, B.A., O'Hara, M., Lochmuller, H. and Karpati, G. (1997) Use of the dog model for Duchenne muscular dystrophy in gene therapy trials. Neuromuscular Disorders, 7 (5). pp. 325-328.

Kay, P.H., Harmon, D., Fletcher, S., Ziman, M., Jacobsen, P.F. and Papadimitriou, J.M. (1997) Variation in the methylation profile and structure of Pax3 and Pax7 among different mouse strains and during expression. Gene, 184 (1). pp. 45-53.

Hilliard, C.M., Fletcher, S. and Yeoh, G.C.T. (1996) Calcium phosphate transfection and cell-specific expression of heterologous genes in primary fetal rat hepatocytes. The International Journal of Biochemistry & Cell Biology, 28 (6). pp. 639-650.

Bartlett, R.J., Winand, N.J., Secore, S.L., Singer, J.T., Fletcher, S., Wilton, S., Bogan, D.J., Metcalf-Bogan, J.R., Bartlett, W.T., Howell, J.M., Cooper, B.J. and Kornegay, J.N. (1996) Mutation segregation and rapid carrier detection of X-linked muscular dystrophy in dogs. American Journal of Veterinary Research, 57 (5). pp. 650-654.

Fletcher, S., Darragh, D., Fan, Y., Grounds, M.D., Fisher, C.J. and Beilharz, M.W. (1993) Specific cloning of DNA fragments unique to the dog Y chromosome. Genetic Analysis: Biomolecular Engineering, 10 (3-4). pp. 77-83.

Beilharz, M.W., Lareu, R.R., Garrett, K.L., Grounds, M.D. and Fletcher, S. (1992) Quantitation of muscle precursor cell activity in skeletal muscle by Northern analysis of MyoD and myogenin expression: Application to dystrophic (mdx) mouse muscle. Molecular and Cellular Neuroscience, 3 (4). pp. 326-331.

Conference Paper

Fletcher, S. (2014) Antisense mediated exon selection to alter gene expression in the study of Disease. In: PAG Asia 2014, 19 - 21 May 2014, Singapore

Fletcher, S. (2013) Antisense suppression of donor splice site mutations in the dystrophin gene transcript. In: 34th Annual Lorne Genome Conference, 17 - 19 February 2013, Victoria, Australia

Conference Item

Pitout, I., Fletcher, S., Etherington, S. and Wilton, S. (2015) A spanner in the works of human Transformer-2-β1 autoregulation may reduce the severity of spinal muscular atrophy. In: 9th Australasian Gene and Cell Therapy Society meeting, 29 April - 1 May, Parkville, Victoria, Australia.

Fletcher, S., Adams, A.M., Greer, K., Johnsen, R. and Wilton, S.D. (2014) Antisense mediated exon selection to alter gene expression. In: PAG Asia 2014, 19 - 21 May 2014, Singapore.

Fletcher, S. (2014) Antisense mediated exon selection to treat human disease. In: Telethon Kids Institute Child Health Research Seminar, 25 July 2014, Perth, Western Australia.

Fletcher, S. (2014) Antisense mediated exon selection to treat human disease. In: HGSA 38th Annual Scientific Meeting, 3 - 6 August 2014, Adelaide, South Australia.

Wilton, S. and Fletcher, S. (2014) Personalised genetic medicines for inherited disorders. In: 5th FIP Pharmaceutical Sciences World Congress (FIP PSWC) 2014: Pharmaceutical Sciences Beyond 2020, 13 - 16 April 2014, Melbourne, VIC.

Wilton, S.D. and Fletcher, S. (2014) Personalised genetic medicines: Hope and Hype. In: The AICC(WA) Murdoch University Science and Society Event, 21 August 2014, Perth, Western Australia.

Fletcher, S. (2014) Research & Science impact of the condition. In: MDWA The Duke of Edinburgh's International Award, 9 April 2014, Perth, W.A.

Fletcher, S. (2014) Targeted therapeutic alternative splicing. In: 16th Annual TIDES Oligonucleotide and Peptide Therapeutics from research through Commercialisation, 12 - 15 May 2014, Rhode Island, USA.

Wilton, S.D. and Fletcher, S. (2014) Therapeutic alternative splicing: Opportunities and challenges. In: ComBio 2014, 28 September - 2 October, Canberra, ACT, Australia.

Fletcher, S. (2014) A clinical trial update on Exon skipping and Duchenne muscular dystrophy. In: Griffiths University. Gene Therapy Seminar, 4 February 2014, Brisbane, QLD.

Fletcher, S. (2013) Antisense therapy for inherited neuromuscular disorers. In: KTRCD Seminar, 30 September 2013, University of Kentucky, Lexington.

Fletcher, S. (2013) PMO-mediated dystrophin exon 23 skipping restores mitochondrial function in the mdx heart. In: Action Duchenne, 9 October 2013, London, England.

Fletcher, S., Viola, H.M., Adams, A.M., Wilton, S.D. and Hool, L.C. (2013) PMO-mediated dystrophin exon 23 skipping restores nitochondrial function in the MDX heart. In: 8th Australasian Gene Therapy Society Meeting, 8 - 10 May 2013, Sydney, Australia.

Wilton, S.D. and Fletcher, S. (2013) Remarkable clinical trials on boys suffering from Duchene Muscular Dystrophy. In: Guest Presentation. Rotary Club of West Perth, 21 Feb 2013, Perth, Western Australia.

Fletcher, S. (2012) Antisense oligomer therapies for neuromuscular disorders. In: West Australian Institute of Medical Research (WAIMR) Seminar Series, October 2012, Perth, Western Australia.

Fletcher, S. (2012) Antisense therapies for DMD and SMA. In: Muscular Dystrophy Foundation International Symposium, April 2012, Nepali Muscular Dystrophy Foundation, Kathmandu.

Fletcher, S., Adams, A.M., Greer, K., Johnsen, R.D., Adkin, C. and Wilton, S.D. (2012) G.P.78 Dystrophin isoforms with incomplete β dystroglycan and syntrophin binding domains retain partial function. In: 17th International Congress of The World Muscle Society, 9 - 13 October 2012, Perth, Western Australia.

Fletcher, S. (2011) Genetic therapies for SMA when, which treatment and what benefit. In: SMA Gene, Respiratory & Movement Seminar, 9 August 2011, Queens College University of Melbourne, Australia.

Fletcher, S. (2011) Splice-switching as a treatment for inherited disorders. In: UWA - Bangkok Research Collaboration Meeting, November 2011, Bangkok, Thailand.

Fletcher, S. (2011) Transient mouse models for the preclinical evaluation of therapeutic dystrophin exon skipping strategies. In: RNA and Oligonucleotide Therapeutics 2011, 4 - 7 December 2011, Cold Spring Harbour, New York.

Wilton, S.D., Adams, A.M., Adkin, C., Greer, K., Johnsen, R. and Fletcher, S. (2011) Transient mouse models for the preclinical evaluation of therapeutic dystrophin exon skipping strategies. In: UK Neuromuscular Translational Research Conference, 29 - 30 March 2011, London, England.

Fletcher, S., Adams, A.M., Adkin, C., Greer, K., Johnsen, R. and Wilton, S. (2011) Transient mouse models for the preclinical evaluation of therapeutic dystrophin exon skipping strategies. In: 7th Australasian Gene Therapy Society Meeting, 4 - 6 May 2011, University of Melbourne, Melbourne.

Fletcher, S. (2011) Transient mouse models for the preclinical evaluation of therapeutic dystrophin exon skipping strategies. In: 16th International Congress of the World Muscle Society, 18 - 22 October 2011, Algarve, Portugal.

Fletcher, S. (2011) Transient mouse models for the preclinical evaluation of therapeutic dystrophin exon skipping strategies. In: 32nd Lorne Genome Conference 2011, 13 - 17 February 2011, Mantra Erskine Resort, Lorne, VIC.

Fletcher, S., Adams, A.M., Johnsen, R.D., Greer, K., Mitrpant, C., Moulton, H.M., Kole, R. and Wilton, S.D. (2010) Concurrent administration of prednisolone and peptide conjugated PMOs is not contra-indicated in the MDX mouse. In: 15th International Congress of The World Muscle Society, 12 - 16 October 2010, Kumamoto, Japan.

Wilton, S.D., Fletcher, S. and Mastaglia, F.L. (2010) Evaluating new therapies & clinical trials: Why, when, which treatment and what benefit? In: MD2010 Conference: Connect, Learn, Share, 9 - 10 September 2010, Perth, Western Australia.

Wilton, S.D. and Fletcher, S. (2010) Implementation of splice switching therapies for duchenne muscular dystrophy. In: OzBio, 26 September - 1 October, Melbourne, Australia.

Fletcher, S., Adams, A.M., Greer, K., Johnsen, R. and Wilton, S.D. (2010) Induced splice-switching to study dystrophin isoform function and expression. In: OzBio, 26 September - 1 October, Melbourne, Australia.

Fletcher, S. (2010) Splice-switching as a treatment for duchenne muscular dystrophy. In: Pathology Update 2010. Royal College of Pathologists Australasia, 26 - 28 February 2010, Melbourne, Australia.

Mitrpant, C., Fragall, C., Fletcher, S. and Wilton, S.D. (2009) Antisense oligomer induced splice manipulation of Survival Motor Neuron exon 7. In: 6th Australasian Gene Therapy Society Meeting, 29 April - 1 May 2009, Kerry Packer Education Centre. Royal Prince Alfred Hospital, Sydney, NSW.

Greer, K., Johnsen, R., Wilton, S. and Fletcher, S. (2009) Exceptions to the reading frame rule in DMD: Will exon skipping be relevant? In: 6th Australasian Gene Therapy Society Meeting, 29 April - 1 May 2009, Kerry Packer Education Centre. Royal Prince Alfred Hospital, Sydney, NSW.

Meloni, P., Stone, L., Fletcher, S. and Wilton, S. (2009) Exon skipping strategies to address DMD-Causing mutations: Personalised genetic therapies. In: 6th Australasian Gene Therapy Society Meeting, 29 April - 1 May 2009, Kerry Packer Education Centre. Royal Prince Alfred Hospital, Sydney, NSW.

Meloni, P., Johnsen, R., Greer, K., Forrest, S., Stone, L., Fletcher, S. and Wilton, S. (2009) Exon skipping strategies to address DMD-causing mutations: Personalized genetic therapies. In: 33rd HGSA Annual Scientific Meeting, 3 - 6 May 2009, Fremantle, Western Australia.

Forrest, S., Meloni, P., Fletcher, S. and Wilton, S. (2009) Exon skipping therapies to address DMD-causing mutations targeting exon blocks. In: 6th Australasian Gene Therapy Society Meeting, 29 April - 1 May 2009, Kerry Packer Education Centre. Royal Prince Alfred Hospital, Sydney, NSW.

Fletcher, S. (2009) Induced non-productive splicing to study gene expression. In: 2009 Inaugural Indian Ocean Rim Muscle Colloquium, 21 - 23 January 2009, Perth, Western Australia.

Fletcher, S., Adams, A.M., Johnsen, R., Greer, K. and Wilton, S. (2009) Induced non-productive splicing to study muscle gene expression. In: 6th Australasian Gene Therapy Society Meeting, 29 April - 1 May 2009, Kerry Packer Education Centre. Royal Prince Alfred Hospital, Sydney, NSW.

Fletcher, S., Adams, A.M., Johnsen, R., Greer, K. and Wilton, S. (2009) Induced non-productive splicing to study muscle gene expression. In: 33rd HGSA Annual Scientific Meeting, 3 - 6 May 2009, Fremantle, Western Australia.

Adams, A.M., Fletcher, S., Ly, T., Johnsen, R. and Wilton, S. (2009) Normalisation of gene expression in MDX mice muscle. In: 6th Australasian Gene Therapy Society Meeting, 29 April - 1 May 2009, Kerry Packer Education Centre. Royal Prince Alfred Hospital, Sydney, NSW.

Barrett, L., Pinniger, G., Fall, A.M., Fletcher, S. and Wilton, S.D. (2009) Optimisation of antisense oligonucleotide cocktails using in silico and in vitro techniques for targeted exon skipping in the dystrophin central rod domain. In: 6th Australasian Gene Therapy Society Meeting, 29 April - 1 May 2009, Kerry Packer Education Centre. Royal Prince Alfred Hospital, Sydney, NSW.

Wilton, S., Adams, A.M., Meloni, P., Johnsen, R., Forrest, S., Greer, K., Stone, L., Mitrpant, C. and Fletcher, S. (2009) Splice intervention to treat duchenne muscular dystrophy and beyond. In: 33rd HGSA Annual Scientific Meeting, 3 - 6 May 2009, Fremantle, Western Australia.

Fletcher, S. (2009) Splice switching as a treatment for Duchenne Muscular Dystrophy. In: 10th Australasian Tissue Banking Forum Scientific, 5 - 8 May 2009, South Perth, Australia.

Fletcher, S. (2009) Splice switching as a treatment for Duchenne muscular dystrophy. In: The Microbiology Seminar Series, 18 September 2009, Perth, Western Australia.

Wilton, S. and Fletcher, S. (2009) Splice switching therapies as personalised genetic treatments: Applications to muscular dystrophy, thalassemia and spinal muscular atrophy. In: 6th Australasian Gene Therapy Society Meeting, 29 April - 1 May 2009, Kerry Packer Education Centre. Royal Prince Alfred Hospital, Sydney, NSW.

Fletcher, S. and Thompson, P. (2009) Theme Four: Genetics. In: LIWA 2009: Lung and Biological Science Symposium, 12 - 13 March 2009, Perth, Western Australia.

Adams, A.M., Fletcher, S., Ly, T., Johnsen, R. and Wilton, S. (2009) Transcriptome patterns show normalization of muscle gene expression after restoration of dystrophin in MDX mice by exon skipping. In: 33rd HGSA Annual Scientific Meeting, 3 - 6 May 2009, Fremantle, Western Australia.

Fletcher, S. (2008) Muscle biology genes and disease. Therapies for muscular dystrophy: An overview. In: 3rd Seminar in International Level on Duchenne Muscular Dystrophy Disables, 8 - 9 November 2008, Muscular Dystrophy Foundation, Nepal.

Fletcher, S. (2008) New therapeutic modalities: Opportunities and challenges. In: BIO International Convention, 17 - 20 June 2008, San Diego, CA.

Mitrpant, C., Fletcher, S., Meredith, C., Bittles, A. and Wilton, S. (2007) Antisense induced exon skipping restores dystrophin in the 4CV mouse model of muscular dystrophy. In: 5th Australasian Gene Therapy Society Meeting, 18 - 20 April 2007, Shine Dome Academy of Science, Canberra.

Steinhaus, J., Fletcher, S., McKitrick, D.J., Holobotovsky, V., Arnolda, L. and Wilton, S. (2007) Antisense oligonucleotide delivery to cardiac muscle: Knocking on a locked door. In: 5th Australasian Gene Therapy Society Meeting, 18 - 20 April 2007, Shine Dome Academy of Science, Canberra.

Adams, A.M., Harding, P.L., Iversen, P.L., Coleman, C., Fletcher, S. and Wilton, S.D. (2007) Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: Cocktails and chemistries. In: 5th Australasian Gene Therapy Society Meeting, 18 - 20 April 2007, Shine Dome Academy of Science, Canberra.

Wilton, S.D., Adams, A.M., Harding, P.L., McClorey, G., Coleman, C. and Fletcher, S. (2007) Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript. In: 5th Australasian Gene Therapy Society Meeting, 18 - 20 April 2007, Shine Dome Academy of Science, Canberra.

Fletcher, S., Honeyman, K., Fall, A.M., Harding, P.L., Johnsen, R.D., Steinhaus, J.P., Moulton, H.M., Iversen, P.L. and Wilton, S.D. (2007) Exon skipping prevents the onset of dystrophic pathology in the MDX mouse. In: 5th Australasian Gene Therapy Society Meeting, 18 - 20 April 2007, Shine Dome Academy of Science, Canberra.

Adams, A.M., McClorey, G., Moulton, H.M., Inversen, P.L., Rasko, J.E., Ryan, M., Fletcher, S. and Wilton, S.D. (2007) Induced dystrophin exon skipping in human muscle explants. In: 5th Australasian Gene Therapy Society Meeting, 18 - 20 April 2007, Shine Dome Academy of Science, Canberra.

Harding, P.L., Adams, A.M., Iversen, P., Fletcher, S. and Wilton, S.D. (2007) Induced exon skipping: AO design is more important than chemistry. In: 5th Australasian Gene Therapy Society Meeting, 18 - 20 April 2007, Shine Dome Academy of Science, Canberra.

Fletcher, S. (2007) Overview of molecular strategies. In: MD2007: Moving Ahead, 13 - 14 April 2007, Perth, Western Australia.

Fletcher, S. (2007) Splicing manipulation for the treatment of duchenne muscular dystrophy. In: ComBio 2007, 22 - 26 September 2007, Sydney Convention & Exhibition Centre, N.S.W.

Fletcher, S. (2007) Systematic dystrophin expression in the MDX mouse: Morphs make more sense. In: 27th Lorne Genome Conference, 11 - 15 February 2007, Erskine House, Lorne, Victoria.

Fletcher, S., Adams, A.M., Harding, P.L., McClorey, G., Muntoni, F., Iversen, P.L. and Wilton, S.D. (2007) A personalised genetic treatment for DMD. In: 5th Australasian Gene Therapy Society Meeting, 18 - 20 April 2007, Shine Dome Academy of Science, Canberra.

Fletcher, S. (2006) Genetic therapies. In: Conference. Turning the Tide. Parent Project Muscular Dystrophy Australia., 27 - 29 October 2006, Brisbane, QLD.

Fletcher, S. (2006) Morpholino antisense oligonucleotide induced dystrophin expression in the MDX mouse. In: Genetic Research Academic Industry Partnership Conference 2006, 3 - 4 August 2006, Perth, Western Australia.

Fletcher, S. (2006) Systematic dystrophin expression in the MDX mouse: Morphs make more sense. In: 26th Lorne Genome Conference, 12 - 15 February 2006, Erskine House, Lorne, Victoria.

Fletcher, S. (2006) A molecular therapy for muscular dystrophy. In: Lotterywest Forum: The Impact of the Genomic Era on Society, 24 October 2006, Perth, Western Australia.

Fletcher, S. (2005) Antisense exon skipping workshop. In: Annual Conference. Parent Project Muscular Dystrophy, 8 - 10 July 2005, Cincinnati, USA.

Wilton, S.D. and Fletcher, S. (2005) Antisense induced redirection of splicing: Will duchenne muscular dystrophy be the thin edge of the wedge? In: 4th Australasian Gene Therapy Society Meeting, 27 - 29 April 2005, Rydges Hotel, Carlton, VIC.

Harding, P.L., Fletcher, S. and Wilton, S.D. (2005) Antisense oligonucleotides and Exon Skipping: Does size matter? In: 4th Australasian Gene Therapy Society Meeting, 27 - 29 April 2005, Rydges Hotel, Carlton, VIC.

Johnson, C., Wilton, S. and Fletcher, S. (2005) In vitro modification of Tissue-Specific alternative splicing of the mouse TPM3 gene with antisense oligonucleotides. In: 4th Australasian Gene Therapy Society Meeting, 27 - 29 April 2005, Rydges Hotel, Carlton, VIC.

Fletcher, S., Honeyman, K., Fall, A., Harding, P., Johnsen, R. and Wilton, S. (2005) In vivo restoration of dystrophin expression. In: 4th Australasian Gene Therapy Society Meeting, 27 - 29 April 2005, Rydges Hotel, Carlton, VIC.

Fletcher, S. (2005) In vivo restoration of dystrophin expression by morpholino antisense oligonucleotides. In: Lions Eye Institute Seminar Series, October 2005, Perth, Western Australia.

Fall, A.M., Honeyman, K., Errington, S.J., Fletcher, S. and Wilton, S.D. (2005) Induction of revertant fibres in the mdx Mouse using antisense oligonucleotides. In: 4th Australasian Gene Therapy Society Meeting, 27 - 29 April 2005, Rydges Hotel, Carlton, VIC.

Fletcher, S. (2005) Molecular therapies for muscular dystrophy: An overview. In: MD2005, 15 - 16 July 2005, Perth, Western Australia.

Gibbs, M., Bouwer, S., Johnson, C., Fletcher, S. and Wilton, S. (2005) A comprehensive mutation screening strategy of the dystrophin gene of DMD patients preceding antisense oligoribonucleotide clinical trials. In: 4th Australasian Gene Therapy Society Meeting, 27 - 29 April 2005, Rydges Hotel, Carlton, VIC.

Fletcher, S. (2004) Manipulating gene expression using antisense oligonucleotides - a strategy to bypass disease causing mutations. In: HGSA Annual Scientific Meeting 2004 & Genes West, 11 - 13 August 2004, Fremantle, Western Australia.

Fletcher, S. (2004) Manipulating gene expression using antisense oligonucleotides: A strategy to bypass disease causing mutations. In: Biochemistry Seminar. University of Western Australia, 17 October 2004, Perth, Western Australia.

Fletcher, S. (2004) Molecular therapies for the treatment of muscular dystrophy. In: Directions for Muscular Dystrophy Conference, 16 - 17 July 2004, University of Southern Queensland, Toowoomba.

Fletcher, S. (2004) Preferred antisense oligonucleotide chemistries to overcome dystrophin mutations. In: 9th World Muscle Society Meeting, 1 - 4 September 2004, Gothenburg, Sweden.

Gebski, B.L., Mann, C.J., Fletcher, S. and Wilton, S.D. (2003) Morpholino antisense oligonucleotides for inducing exon skipping. In: 3rd Meeting of Australasian Gene Therapy Society, 30 April - 2 May 2003, Queensland Institute of Medical Research, Brisbane.

Errington, S.J., Mann, C.J., Fletcher, S. and Wilton, S.D. (2003) Multiple exon skipping in the dystrophin gene: A more effective therapy? In: 3rd Meeting of Australasian Gene Therapy Society, 30 April - 2 May 2003, Queensland Institute of Medical Research, Brisbane.

Wilton, S.D., Mann, C.J., McClorey, G., Honeyman, K., Gebski, B.L., Errington, S.J., Saxena, A. and Fletcher, S. (2003) Redirecting dystrophin pre-mRNA splicing using antisense oligonucleotides: An overview. In: 3rd Meeting of Australasian Gene Therapy Society, 30 April - 2 May 2003, Queensland Institute of Medical Research, Brisbane.

Fletcher, S. (2003) Redirecting pre-mrna splicing using antisense oligonucleotides. In: The XIX International Congress of Genetics: Genomes - The Linkage of Life, 6 - 11 July 2003, Melbourne Convention and Exhibition Centre, Melbourne, VIC.

Fletcher, S. (2003) Stem cells - a 20th Century Panacea? In: Neurological Expo 2003, 11 - 13 November 2003, The Neurological Council of Western Australia Inc. Perth, WA.

Martino, D., Fletcher, S., Grounds, M. and Wilton, S.D. (2003) Transient suppression of the Myostatin gene transcript: A comparison of different antisense nucleic acid mechanisms. In: 3rd Meeting of Australasian Gene Therapy Society, 30 April - 2 May 2003, Queensland Institute of Medical Research, Brisbane.

Fletcher, S. (2002) Embryonic stem cells and the fountain of youth: Fact or fantasy. In: Cloning Stem Cell Research and Transgenics, 24 May 2002, Western Australian Reproductive Technology Council/Murdoch University. Perth, WA.

Fletcher, S., Ly, T., Duff, R.M., Howell, J.M., Mann, C.J. and Wilton, S.D. (2001) Cryptic splicing involving the splice site mutation in the canine model of Duchenne Muscular Dystrophy. In: 2nd Meeting of the Australasian Gene Therapy Society, 27 - 29 April 2001, Sydney, Australia.

Howell, J.Mc.C., Pari, G., Fletcher, S., Wilton, S., Davies, L.J., Lloyd, F., Nalbantoglu, J., Collins, T., DiMauro, S., Kakulas, B.A. and Karpati, G. (2001) Gene therapy trials in the ovine model of McArdle's disease. In: 2nd Meeting of the Australasian Gene Therapy Society, 27 - 29 April 2001, Sydney, Australia.

Mann, C.J., Ly, T., Fletcher, S., Cheng, A.J., Lloyd, F.P., Morgan, J., Partridge, T. and Wilton, S.D. (2001) Restoration of dystrophin expression in the MDX mouse using antisense oligonucleotides in a gene "knock-in" approach. In: 2nd Meeting of the Australasian Gene Therapy Society, 27 - 29 April 2001, Sydney, Australia.

Fletcher, S. (1999) Gene therapy trials in Golden Retriever muscular dystrophy. In: Inaugural Meeting of the Australian Gene Therapy Society, 22 - 23 February 1999, The Murdoch Institute, Royal Children's Hospital. Melbourne, Australia.

Howell, J.M., Pari, G., Davies, L., Fletcher, S., Wilton, S.D., Collins, T., Crerar, M.M., Nalbantoglu, J., Shoubridge, E., Jani, A., Tsujino, S., Shankse, S., Kakulas, B.A., DiMauro, S. and Karpati, G. (1999) Investigations of gene therapy for McArdle's disease using the sheep model. In: 4th International Congress of the World Muscle Society, 14 - 16 October 1999, Antalya, Turkey.

Fletcher, S. (1998) Evidence for multiple functions of PAX 7. In: IX International Congress on Neuromuscular Diseases, 30 August - 4 September 1998, Adelaide, South Australia.

Fletcher, S. (1998) Gene therapy trials in the GRMD model. In: ANRI Symposium on Gene Therapy and Neuromuscular Disorders, 28 August 1998, Perth, Western Australia.

Wilton, S.D., Lloyd, F., Fletcher, S. and Kole, R. (1998) Targeted dystrophin gene processing using antisense oligonucleotides. In: 3rd International Congress of World Muscle Society, 29 - 30 May 1998, Naples, Italy.

Ziman, M., Fletcher, S. and Kay, P. (1997) Evidence for alternate Pax7 transcripts in skeletal muscle, brain and other organs of adult mice. In: XIII International Congress of Neuropathology, 7 - 12 September 1997, Perth, Australia.

Fletcher, S., Kay, P.H., Harmon, D., Robertson, T. and Papadimitriou, J.M. (1997) Evidence that Pax7 contains two polymorphic homeoboxes, one of which has a rearrangement associated with enhanced skeletal muscle regrowth. In: 8th Annual Combined Biological Sciences Meeting, 15 August 1997, Perth, Western Australia.

Fletcher, S., Kay, P.H., Harmon, D., Robertson, T. and Papadimitriou, J.M. (1997) Evidence that Pax7 contains two polymorphic homeoboxes, one of which has a rearrangement associated with enhanced skeletal muscle regrowth. In: XIII International Congress of Neuropathology, 7 - 12 September 1997, Perth, Australia.

Fletcher, S. (1997) Use of the Golden Retriever dog model for Duchenne muscular dystrophy in gene therapy trials. In: The Boden Conference on Gene Therapy, 4 - 7 February 1997, Thredbo, Victoria.

Fletcher, S. (1995) Snap-back SSCP: specific introduction of conformational changes for mutation detection. In: 5th Annual Queenstown Molecular Biology Meeting, 13 - 18 August 1995, Queenstown, New Zealand.

Fletcher, S., Lim, L., Dye, D. and Wilton, S. (1995) "Snap-back" SSCP: specific introduction of conformational changes for mutation detection. In: 6th Combined Biological Sciences Meeting, Perth, Western Australia.

Fletcher, S. (1992) Northern analysis of regenerative activity in crush injured and dystrophic mdx muscle. In: Combined Biological Sciences Meeting, 24 July 1992, Mount Claremont, Perth.

Fletcher, S. (1991) Quantitation of growth and regenerative activity in skeletal muscle. In: Symposium. Molecular Biology of Muscle/Society for Experimental Biology, 9 - 12 September 1991, University of Birmingham, UK.

Fletcher, S. Converting DMD to BMD: A genetic medicine. In: MD2003, 9 - 10 May 2003, Perth, Western Australia.

Fletcher, S. Northern analysis of regenerative activity in crush injured and dystrophic (mdx) muscle. In: 14th Annual Conference on the Organisation and Expression of the Genome, 17 - 21 February 1992, Lorne, Victoria.

Book Chapter

Greer, K., Fletcher, S. and Wilton, S.D. (2018) Skipping of duplicated dystrophin exons: In Vitro induction and assessment. In: Yokota, T. and Maruyama, R., (eds.) Exon Skipping and Inclusion Therapies. Humana Press, pp. 219-228.

Aaldering, L., Krishnan, S., Fletcher, S., Wilton, S. and Veedu, R. (2016) Aptamers as therapeutic tools in neurological diseases. In: Veedu, R.N., (ed.) Aptamers: Tools for Nanotherapy and Molecular Imaging. Pan Stanford, pp. 151-167.

Adkin, C., Fletcher, S. and Wilton, S.D. (2012) Optimizing Splice-Switching Oligomer Sequences Using 2′-O-Methyl Phosphorothioate Chemistry. In: Aartsma-Rus, A., (ed.) Exon Skipping: Methods and Protocols. Humana Press, pp. 169-188.

Wilton, S.D. and Fletcher, S. (2006) Redirecting splicing to address dystrophin mutations: Molecular By-pass surgery. In: Jeanteur, P., (ed.) Alternative Splicing and Disease. Springer Berlin Heidelberg, pp. 161-197.

Book

Barrett, L.W., Fletcher, S. and Wilton, S.D. (2013) Untranslated gene regions and other Non-coding elements: Regulation of eukaryotic gene expression. Springer, Dordrecht, NL.

Creative Output

Wilton, S.D., Murphy, L. and Fletcher, S. (2010) Molecular Bypass. [Television] [Creative Output]

This list was generated on Tue May 21 21:52:27 2019 UTC.